Rs 3.5 lakh fine on Fortis Healthcare over violation of LODR rules: SEBI

Published On 2021-10-27 07:54 GMT   |   Update On 2021-10-27 07:54 GMT

New Delhi: Markets regulator Sebi on Monday imposed a penalty of Rs 3.5 lakh on Fortis Healthcare Holdings for flouting norms with respect to its non-convertible debentures.

The fine has been levied for violating several provisions of LODR (Listing Obligations and Disclosure Requirements) rules, Sebi said in an order.

The regulator noted that Fortis did not provide information on the payment of interest for certain ISINs (International Securities Identification Numbers).

ISIN code, which has 12 characters, is used for uniquely identifying securities like stocks, bonds warrants and commercial papers.

Among others, Sebi said the company did not provide hard copies of annual reports to holders of NCDs (Non-Convertible Debentures) who had requested for the same.

Further, the company was required to fix a record date for purpose of payment of interest, dividend and payment of redemption as specified under the norms. However, the firm failed to comply with the provision.

Fortis did not take prior approval for any material modification in the structure of NCDs, according to Sebi.

For these violations, the regulator levied a "penalty of Rs 3.5 lakh on the notice i.e. Fortis Healthcare Holdings Private Limited."

Read also: SEBI junks proceedings against Fortis statutory auditor for alleged role in fund diversion

The Securities and Exchange Board of India (Sebi) had received references from the Debenture Trustees of NCDs issued by Fortis alleging that the company had not provided any information on the payment of interest for certain ISINs.

Thereafter, the regulator conducted an examination to ascertain the compliance of relevant regulations pertaining to the disclosures/ filings with stock exchanges by Fortis as required under the LODR rules for the financial years 2017-18, 2018-19 and 2019-20 (up to September 30, 2019) with respect to the NCDs issued by the firm.

Read also: Bain Capital backed Emcure Pharma files draft IPO papers with SEBI

Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News